Japanese medical technology start-up Ubie receives $18.7 million round B financing to further accelerate commercialization of its hospital SaaS products

Read: Japan's Ubie gets huge Round B financing with "Software as a Service"Artery Network (microsignal: vcbeat) learned that on June 4, local time, Ubie, a Japanese medical technology start-up, announced the completion of a $18.7 million round b financing and a strategic partnership with investment institutions, led by Suzukenthe start-up will use the new money to expand its medical technology platform, product development capabilities, and staff its diverse sales and engineering teamsThe funds will enable the company to reach new partners and customers across Japan and rapidly expand its hospital SaaS product, Ubie for Hospital, and the use of its consumer app, Dr Ubie, an artificial intelligence symptom checker, Ubie also plans to expand its overseas operations in the futureUbie, a Tokyo-based medical technology start-up that offers medical products based on artificial intelligenceThe first product, Ubie for Hospital, also known as AI Monshin, is an artificial intelligence-driven medical questionnaire software that supports the creation of clinical documentation under expert supervisionUbie's SaaS solution, launched in 2017, combines multi-workflow enhancements and clinical decision support (CDS)patients will answer questions from AI Monshin in the waiting room, and their answers will be translated and summarized into EHR-compatible textNext, the doctor will review the results in the clinic, and finally, the information collected by the doctor will be analyzed and integrated to examine and diagnose the patientMore than 200 medical institutions in Japan are using their products, according to the latest data from the startup in January 2020's second product is The Consumer-oriented Artificial Intelligence Symptom Checker Dr Ubie, a doctor-supervised symptom-checking appUsers can learn about their symptoms by answering questions and learning how to respond to them based on disease feedbackat the height of the outbreak in Japan last month, Ubie launched an additional new coronary pneumonia triage system on its Ubie for Hospital platform to help doctors and healthcare workers make better and more efficient diagnosesUbie says its online screening and classification tool can quickly distinguish between patients who may be truly infected with COVID-19 and life-threatening diseases, which also helps prevent hospital overcrowding and in-hospital infections"Today, technology supports every aspect of life," says Kota Kubo, co-founder of Ubie"In the current outbreak of new crown pneumonia, new technologies will be used for disease surveillance and prevention However, many of the technologies and products we use every day in Japan are developed by foreign technology companies As a Japanese technology entrepreneur, I am disappointed by this fact The outbreak of new crown pneumonia is still severe, but the progress made so far has proved to the world that Japan's health care system is effective and resilient I believe it is now our turn to support and protect our medical staff said: "I firmly believe that our company will play a key role in responding to the current crisis Our mission to 'develop health care guidelines for everyone' has become even more important during the critical times of the epidemic We began developing artificial intelligence-based symptom checking and clinical decision support technology systems in 2013 to make healthcare accessible to everyone by creating a medical 'search engine' With the help of a new round of financing, with the full support of all helpers, we will do our utmost to realize the company's mission as soon as possible Suzuken Suzuken was founded in 1932 and headquartered in Nagoya, Japan, as a pharmaceutical company that manufactures and sells prescription drugs It has a wide range of medical practices, including the development and production of new drugs, support for pharmaceutical manufacturers, pharmacy insurance and care